Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Monitoring metabolic side effects of atypical antipsychotics in people with an intellectual disability.

Teeluckdharry S, Sharma S, O'Rourke E, Tharian P, Gondalekar A, Nainar F, Roy M.

J Intellect Disabil. 2013 Sep;17(3):223-35. doi: 10.1177/1744629513495261. Epub 2013 Jun 25.

PMID:
23801356
2.

[Drawing up guidelines for the attendance of physical health of patients with severe mental illness].

Saravane D, Feve B, Frances Y, Corruble E, Lancon C, Chanson P, Maison P, Terra JL, Azorin JM; avec le soutien institutionnel du laboratoire Lilly.

Encephale. 2009 Sep;35(4):330-9. doi: 10.1016/j.encep.2008.10.014. Epub 2009 Jul 9. French.

PMID:
19748369
3.

Determinants of physical health parameters in individuals with intellectual disability who use long-term antipsychotics.

de Kuijper G, Mulder H, Evenhuis H, Scholte F, Visser F, Hoekstra PJ.

Res Dev Disabil. 2013 Sep;34(9):2799-809. doi: 10.1016/j.ridd.2013.05.016. Epub 2013 Jun 20.

PMID:
23792429
4.

Safety of antipsychotics in people with intellectual disability.

Frighi V, Stephenson MT, Morovat A, Jolley IE, Trivella M, Dudley CA, Anand E, White SJ, Hammond CV, Hockney RA, Barrow B, Shakir R, Goodwin GM.

Br J Psychiatry. 2011 Oct;199(4):289-95. doi: 10.1192/bjp.bp.110.085670.

PMID:
21816867
5.

Effects of controlled discontinuation of long-term used antipsychotics on weight and metabolic parameters in individuals with intellectual disability.

de Kuijper G, Mulder H, Evenhuis H, Visser F, Hoekstra PJ.

J Clin Psychopharmacol. 2013 Aug;33(4):520-4. doi: 10.1097/JCP.0b013e3182905d6a.

PMID:
23775048
6.

Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring.

De Hert M, van Eyck D, De Nayer A.

Int Clin Psychopharmacol. 2006 Mar;21 Suppl 2:S11-5. Review.

PMID:
16601508
7.

[Antipsychotic prescription assessment in general practice: metabolic effects].

Gignoux-Froment F, de Montleau F, Saravane D, Verret C.

Encephale. 2012 Dec;38(6):453-9. doi: 10.1016/j.encep.2011.12.006. Epub 2012 Jan 23. French.

PMID:
23200610
9.

The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists.

Newcomer JW, Nasrallah HA, Loebel AD.

J Clin Psychopharmacol. 2004 Oct;24(5 Suppl 1):S1-6.

PMID:
15356414
10.

Awareness of metabolic concerns in patients with bipolar disorder: a survey of European psychiatrists.

Bauer M, Lecrubier Y, Suppes T.

Eur Psychiatry. 2008 Apr;23(3):169-77. Epub 2007 Dec 21.

PMID:
18160267
11.

Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health Administration.

Shi L, Ascher-Svanum H, Chiang YJ, Zhao Y, Fonseca V, Winstead D.

BMC Psychiatry. 2009 Dec 18;9:80. doi: 10.1186/1471-244X-9-80.

12.

Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders.

Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophrenia and Related Disorders.

Aust N Z J Psychiatry. 2005 Jan-Feb;39(1-2):1-30. Review.

PMID:
15660702
13.

Psychiatrists' attitudes toward metabolic adverse events in patients with schizophrenia.

Sugawara N, Yasui-Furukori N, Yamazaki M, Shimoda K, Mori T, Sugai T, Suzuki Y, Someya T.

PLoS One. 2014 Jan 23;9(1):e86826. doi: 10.1371/journal.pone.0086826. eCollection 2014.

14.

Cardiovascular risk factors (diabetes, hypertension, hypercholesterolemia and metabolic syndrome) in older people with intellectual disability: results of the HA-ID study.

de Winter CF, Bastiaanse LP, Hilgenkamp TI, Evenhuis HM, Echteld MA.

Res Dev Disabil. 2012 Nov-Dec;33(6):1722-31. doi: 10.1016/j.ridd.2012.04.010. Epub 2012 Jun 13.

PMID:
22699246
15.

Creation of a metabolic monitoring program for second-generation (atypical) antipsychotics.

Reeves R, Kaldany H, Lieberman J, Vyas R.

J Correct Health Care. 2009 Oct;15(4):292-301. doi: 10.1177/1078345809340424. Epub 2009 Jul 21.

PMID:
19622845
16.

Metabolic syndrome in schizophrenia: a comparative study of antipsychotic-free/naïve and antipsychotic-treated patients from India.

Pallava A, Chadda RK, Sood M, Lakshmy R.

Nord J Psychiatry. 2012 Jun;66(3):215-21. doi: 10.3109/08039488.2011.621977. Epub 2011 Oct 24.

PMID:
22017264
17.

Clinical monitoring and management of the metabolic syndrome in patients receiving atypical antipsychotic medications.

Hasnain M, Vieweg WV, Fredrickson SK, Beatty-Brooks M, Fernandez A, Pandurangi AK.

Prim Care Diabetes. 2009 Feb;3(1):5-15. doi: 10.1016/j.pcd.2008.10.005. Epub 2008 Dec 10. Review.

PMID:
19083283
18.

Using antipsychotic agents in older patients.

Alexopoulos GS, Streim J, Carpenter D, Docherty JP; Expert Consensus Panel for Using Antipsychotic Drugs in Older Patients.

J Clin Psychiatry. 2004;65 Suppl 2:5-99; discussion 100-102; quiz 103-4. Review.

19.
20.

Supplemental Content

Support Center